Grace Therapeutics
GRCE
Grace Therapeutics (GRCE) earnings history
Most recent quarter
- Fiscal period
- Q1 2026
- Period end
- Jun 30, 2025
- EPS actual
- −$0.21
- EPS estimate
- −$0.22
- EPS surprise
- +4.55%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2026 | Aug 12, 2025 | −$0.22 | −$0.21 | +4.55% | $0.00 | SEC |
| Q4 2025 | Jun 23, 2025 | −$0.28 | $0.11 | +139.64% | $0.00 | SEC |
| Q3 2025 | Feb 13, 2025 | −$0.34 | −$0.36 | −7.46% | $0.00 | SEC |
| Q2 2025 | Nov 13, 2024 | −$0.37 | −$0.30 | +18.92% | $0.00 | SEC |
| Q1 2025 | Aug 9, 2024 | −$0.27 | −$0.24 | +9.43% | $0.00 | SEC |
| Q4 2024 | Jun 21, 2024 | −$0.35 | −$0.17 | +51.43% | $0.00 | SEC |
| Q3 2024 | Feb 12, 2024 | −$0.23 | −$0.21 | +8.70% | $0.00 | SEC |
| Q2 2024 | Nov 13, 2023 | −$0.26 | −$0.43 | −65.38% | $0.00 | SEC |
| Q1 2024 | Aug 11, 2023 | −$0.28 | −$0.54 | −92.86% | $0.00 | SEC |
| Q4 2023 | Jun 23, 2023 | −$0.84 | −$3.90 | −364.29% | $0.00 | SEC |
| Q3 2023 | Feb 14, 2023 | −$0.74 | −$0.54 | +27.03% | $0.00 | SEC |
| Q2 2023 | Nov 14, 2022 | $0.00 | −$0.66 | +0.00% | $0.00 | SEC |
| Q1 2023 | Aug 11, 2022 | $0.00 | −$0.60 | +0.00% | $0.00 | SEC |
| Q4 2022 | Jun 21, 2022 | −$0.78 | −$0.54 | +30.77% | $0.00 | SEC |
| Q3 2022 | Feb 14, 2022 | −$0.48 | −$0.54 | −12.50% | $0.00 | SEC |
| Q2 2022 | Nov 10, 2021 | $0.00 | −$0.18 | +0.00% | $0.00 | — |
| Q1 2022 | Aug 12, 2021 | $0.00 | −$0.48 | +0.00% | $0.00 | — |
| Q4 2021 | Jun 22, 2021 | −$1.92 | −$1.44 | +25.00% | $0.00 | — |
| Q3 2021 | Feb 9, 2021 | −$1.92 | −$1.44 | +25.00% | $81,000.00 | — |
| Q2 2021 | Nov 16, 2020 | −$2.65 | −$2.88 | −8.81% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Grace Therapeutics (GRCE) last report earnings?
Grace Therapeutics last reported on Aug 12, 2025, covering fiscal Q1 2026.
Did GRCE beat earnings estimates?
Yes. Grace Therapeutics reported EPS of −$0.21 for Q1 2026 against a −$0.22 estimate — a 4.55% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.